What's new?
10/07/2018

Paris, France, July 10th. 2018. Sofinnova Partners, a leading venture capital firm specialized in Life Sciences, today announced that Otsuka Holdings is acquiring its portfolio company ReCor Medical, a medical device company specialized in the treatment of hypertension. The terms of the acquisition are being withheld due to non-disclosure obligations.

ReCor Medical was created in 2009 by Sofinnova Partners, Mano Iyer – who was then entrepreneur-in-residence at Sofinnova Partners and now Chief Operating Officer of ReCor – and Professor Jacques Seguin, MD, who became a large private investor in ReCor. Prof. Seguin was previously founder and CEO of CoreValve, a past Sofinnova portfolio company and a leader in the transcatheter valve replacement space, which was sold to Medtronic. Sofinnova Partners was the sole venture capital investor in ReCor Medical and remained its largest shareholder until the sale to Otsuka.

ReCor Medical is an innovative medical device company that developed the Paradise System, a proprietary ultrasound ablation system for renal denervation (RDN). RDN is a new potential therapeutic approach for the treatment of hypertension, one of the most prevalent medical conditions. ReCor recently announced positive results of its landmark RADIANCE-HTN SOLO hypertension study at EuroPCR 2018.

Antoine Papiernik, Managing Partner at Sofinnova Partners and ReCor Board Member, said: “ReCor perfectly illustrates our investment strategy: we worked hand-in-hand with Mano Iyer to create the business vision and plan for ReCor. We then founded and funded the company, and opened our network of experts, key opinion leaders and board members to help grow it. We brought trusted entrepreneurs Jay Watkins as Chairman and Andy Weiss as CEO to help guide and operate the company through to a corporate transaction to our partner Otsuka.”

Jay Watkins, Chairman of ReCor Medical said: “Sofinnova Partners remains one of few VCs willing to fund early-stage med-tech ventures targeting large and important new markets. The firm played a critical role throughout ReCor’s life, and has proven to be a reliable, value-added partner for the company. The field of renal denervation has been a complex one over the last few years with periods of euphoria and periods of doubt. Sofinnova Partners’ support remained constant throughout, helping to build a strong partnership with Otsuka and then navigate through the challenges to a very successful trade sale.”

Mano Iyer, Founder and COO of ReCor Medical added: “ReCor is a success story because Sofinnova Partners, consistent with its philosophy, saw the value of an opportunity which did not yet exist. It had the vision to create and fund the company, not only in the very beginning, but also during the critical early years. Despite the dramatic swings in the field, Sofinnova Partners’ confidence in me and in the management team was essential to keep us motivated when others lost hope. This great exit is therefore particularly sweet.”

Andrew M. Weiss, CEO of ReCor Medical adds: “I came to ReCor thanks to Antoine Papiernik’s introduction to the company. With his help, our team developed the partnership with Otsuka and was able to remain focused on value creation. The recent announcement of our positive RADIANCE-HTN SOLO study results and now the merger with Otsuka demonstrate that our teamwork with Sofinnova Partners was successful. We now have an opportunity to transform the treatment of hypertension and benefit millions of potential patients while providing a solid return for our investors. I look forward to continuing to work to make this technology a possible standard of care in hypertension treatment”.

For more information, please contact:
SOFINNOVA PARTNERS
International: Anne Rein
Tel: +33 6 03 35 92 05
e-mail: anne.rein@strategiesimage.com
United States: Kate Barrette
Tel: +1 212 223 0561
e-mail: kbarrette@rooneyco.com

About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together a team of professionals from all over Europe, the US and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a lead or cornerstone investor in seed, start-ups, corporate spin-offs and late stage companies. It has backed nearly 500 companies over more than 45 years, creating market leaders around the globe. Today, Sofinnova Partners has over €1.9 billion under management. For more information: www.sofinnova.fr

About ReCor Medical, Inc.
ReCor Medical is a medical device company that designs and manufactures the Paradise System, a proprietary ultrasound ablation system for renal denervation (RDN). RDN is a new potential therapeutic approach for the treatment of hypertension, one of the most prevalent medical conditions. The Paradise System is approved for sale in the EU and bears a CE mark, but is not approved for sale in the United States. The System’s intravascular catheters denervate renal nerves by combining the protection of water-based cooling of the renal artery with high intensity ultrasound energy for circumferential renal nerve ablation. The Paradise System has been studied in clinical trials of approximately 300 patients to date. Following the positive outcomes of the RADIANCE-HTN SOLO trial, ReCor will continue its evaluations of Paradise in RADIANCE-HTN TRIO (a feasibility study of patients with resistant hypertension) and REQUIRE (a pivotal study of patients with resistant hypertension in Japan and Korea), and launch the RADIANCE II pivotal study (a study of patients with moderate hypertension) in the United States and Europe.
http://www.recormedical.com/

About Otsuka Holdings Co., Ltd. and Otsuka Medical Devices Co., Ltd.
Otsuka Holdings Co., Ltd. is the holding company of the Otsuka group, a global healthcare group headquartered in Tokyo, Japan. With operations in pharmaceuticals, nutraceuticals, medical devices and other health-related businesses, the group generated worldwide sales of JPY1,240 billion in the fiscal year ended December 2017.
http://www.otsuka.com/en/

Established in 2011, Otsuka Medical Devices Co., Ltd. is a fully-owned subsidiary of Otsuka Holdings and one of its core operating subsidiaries. Otsuka Medical Devices focuses on the development and commercialization of endovascular devices that provide new therapeutic options in areas where patient needs cannot be met through pharmaceutical or other conventional treatment.
Otsuka Medical Devices conducts the REQUIRE trial for renal denervation in hypertensive patients (n=140), who are uncontrolled on 3 or more medications including a diuretic, in Japan and Korea through its subsidiary JIMRO Co., Ltd.
http://www.omd.otsuka.com/en/

22/05/2018

First-of-its-Kind Lesion Preparation Tool Fractures Calcium in CAD with Sonic Pressure Waves, Enabling Optimal Stent Delivery and Expansion While Minimizing Trauma

First Patient Enrolled in DISRUPT CAD II Post-Market Study Fremont, Calif. — May 21, 2018 — Shockwave Medical, a pioneer in the treatment of calcified cardiovascular disease, today announced the European commercial availability of Intravascular Lithotripsy (IVL) for calcified coronary artery disease (CAD), as well as the enrollment of the first patient in the DISRUPT CAD II post-market study by Professor Jonathan Hill, MD, at King’s College in London. Coronary artery calcium physically impairs stent expansion,i and is perhaps the single most important predictor of early stent thrombosis and restenosis after stent procedures.ii iii iv Current calcium modification treatments, which can be difficult to perform, only address the burden of intimal calcium with varying degrees of success and result in an increased risk for adverse events since they don’t differentiate between the calcific lesion and soft intimal tissue. IVL is a novel therapy designed to treat calcified artery blockages with sonic pressure waves historically used to treat patients with kidney stones. The technology minimizes trauma within the artery by delivering pulsatile sonic pressure waves locally to effectively fracture both intimal and medial calcium in the artery wall but pass through surrounding soft vascular tissue in a safe manner. Additionally, IVL requires no specialized training with its familiar technique, and it allows physicians to use their own guidewire of choice to seamlessly integrate into the existing workflow. “For many years, addressing challenging calcium in patients with complex coronary artery disease has been a balancing act weighing the risk of certain therapies with their clinical benefit,” said Jean Fajadet, MD, co-principal investigator of the DISRUPT CAD II study and co-director of the Interventional Cardiovascular Group at Clinique Pasteur in Toulouse, France. “Now with the availability of IVL, we finally have an intuitive calcium modification tool that offers the maximum benefit in increasing vessel compliance prior to stent implantation with minimal safety risks.”
The technology previously obtained CE Mark on the strength of the safety and efficacy data in the DISRUPT CAD study, a pre-market, prospective multi-center single arm study conducted at seven centers in Europe and Australia that enrolled 60 patients with complex calcified CAD. The newly initiated DISRUPT CAD II study is a post-market study that will enroll an additional 120 patients at sites across the globe, including Italy, Germany, Netherlands, Denmark, France, UK, Spain, Sweden and Belgium.
SPL 62245

“Having used Intravascular Lithotripsy in both a clinical trial setting as well as in our everyday clinical practice for complex patients, it’s clear that this is a game-changing technology for the treatment of calcified coronary artery disease,” said Prof. Hill. “A more widespread introduction of this technology will significantly augment our ability to modify calcific lesions. It is a highly accessible technology, which is simple to use and can be rapidly deployed in the cath lab.” The Shockwave Coronary IVL System complements the existing large and small diameter peripheral IVL catheters, which have been available in Europe for the treatment of calcified peripheral disease from the iliac arteries down to the foot since 2015 and early 2018, respectively. The Shockwave Coronary IVL System, similar to the peripheral IVL systems, includes a compact, battery-powered generator, a simple and quick hand-held connector cable with a single therapy delivery button and an intuitive catheter, which houses an array of lithotripsy emitters enclosed in an integrated balloon. The catheter is delivered to a lesion similar to standard interventional techniques and on the physician’s choice of guidewire. “The introduction of the Shockwave Coronary IVL System represents a significant advance not only for the treatment of calcified coronary artery disease, but also for the future growth of the company by diversifying our portfolio of IVL devices,” said Doug Godshall, CEO of Shockwave Medical. “Our initial experience with the technology over the last few months has bolstered our belief in what a meaningful impact this technology will have in the hands of operators across the globe.” Shockwave IVL catheters are now commercially available for coronary artery disease in Europe; they are not available in the United States.

About Shockwave
Medical’s Intravascular Lithotripsy System Shockwave Medical’s IVL System leverages similar principles to urologic lithotripsy, which has been used as a safe and effective treatment for kidney stones for several decades. The generator produces energy that travels through the connector cable and catheter to an array of miniaturized lithotripsy emitters located near the calcified lesion. With the integrated balloon expanded to ultra-low pressure, a small electrical discharge at the emitters vaporizes the fluid within the balloon, creating a rapidly expanding bubble that collapses within microseconds. The bubble’s expansion and collapse generates a series of sonic pressure waves that travel through the fluid-filled balloon and pass through soft vascular tissue, selectively cracking any hardened calcified plaque inside the vessel wall. After the calcium has been fractured, the integrated balloon can be expanded, performing angioplasty safely at low pressures.
The presence of calcium can make coronary interventions more difficult and lead to complications during the procedure and escalating healthcare costs. Shockwave Medical’s IVL system was designed to minimize trauma to the artery, simplify the procedure, and optimize outcomes for CAD patients. To view an animation of the Intravascular Lithotripsy System visit http://shockwavemedical.com.

Shockwave Medical, based in Fremont, Calif., is developing and commercializing innovative intravascular lithotripsy technology for the treatment of calcified peripheral vascular, coronary vascular and heart valve disease. For more information, visit www.shockwavemedical.com.

27/04/2018

• Lead investor Venrock joined by Andera, Cormorant, HBM Healthcare Investments, Fresenius Medical Care Ventures GmbH, Sofinnova Partners, Apple Tree Partners and MedImmune
• Corvidia nears completion of its Phase 2 genetically-defined clinical trial targeting chronic kidney disease
• Funding supports innovative approach to drug development, progressing lead clinical program, advancing pre-clinical programs and adding key talent

Waltham, MA, April 25, 2018 — Corvidia Therapeutics Inc., a leading clinical stage biotechnology company, today announced the close of a $60 million USD Series B funding round. The financing will accelerate growth of Corvidia’s ongoing clinical programs, expand scientific and market access capabilities and explore new treatment areas.

Venrock led the Series B financing and was joined by five additional new investors: Andera (formerly Edmond de Rothschild), Cormorant Asset Management, HBM Healthcare Investments, Fresenius Medical Care Ventures GmbH and Venrock Healthcare Capital Partners (VHCP). Series A investors Apple Tree Partners, MedImmune, the global biologics Research and Development arm of AstraZeneca, and Sofinnova Partners, the founding seed investor, also participated in this round.

“We are extremely pleased to have reached such an important milestone in Corvidia’s advancement as a biotechnology company,” said Marc de Garidel, Chief Executive Officer of Corvidia Therapeutics Inc. “This funding is critical to accelerating our clinical programs and adding the necessary scientific and market access infrastructure which will drive our growth in developing precision therapies for patients across a range of complex diseases.” Mr. de Garidel, former Chairman and Chief Executive Officer of Ipsen SA, joined Corvidia in March 2018.

Corvidia Therapeutics is nearing completion of a Phase 2 clinical trial for a genetically-defined patient population living with advanced chronic kidney disease. Presently, the Company is scientifically-focused on cardiovascular indications utilizing the study of genetic variations to ultimately deliver precise treatments to specific patients who have an unmet medical need. The Series B funding will be used to progress the lead clinical programs in chronic kidney disease and beyond as well as advance pre-clinical programs. The Company will add new talent to support these advancing programs.

“Corvidia’s innovative approach to cardiovascular drug development allows them to parse complex, heterogeneous conditions and validate disease pathways in patient subpopulations before beginning clinical trials,” says Karim Helmy MD, PhD, Vice President, Venrock. “We have confidence that Corvidia’s highly-respected and experienced team will continue to identify critical therapeutic targets for these devastating diseases through their pioneering approach.”

Several changes to Corvidia’s executive management team were announced in concert with the closing of Series B funding. Four of the founding executive team members have been named to new positions: Rahul Kakkar MD is Chief Medical Officer and Chief Strategy Officer; Matt Devalaraja, DVM, PhD is Executive Vice President and Head of Research and Development; Ram Aiyar, PhD, MBA is Executive Vice President and Head of Business Development. Corvidia’s former chief executive officer, Michael Davidson MD, was named Chief Science Officer upon the appointment of Mr. de Garidel as CEO.

About Corvidia Therapeutics Inc.
Corvidia Therapeutics Inc. is a clinical stage biotechnology company based in Waltham, Massachusetts pioneering the next generation of cardiovascular and cardio-renal therapies. Corvidia’s pipeline programs utilize functional genomics to precisely identify patients with unique sensitivity to specific biologic pathways, allowing for rapid development and an accelerated path-to-market for drugs targeting those pathways. Among our portfolio of novel therapeutic candidates, we presently have an experimental therapy in Phase 2 development for a genetically-defined patient population with chronic kidney disease. Corvidia’s other preclinical programs are in various stages of development and are focused on cardiovascular diseases. For more information, please visit www.corvidiatx.com

Press Inquiries:
McDougall Communications on behalf of Corvidia Therapeutics Inc.
Contact: Elizabeth Harness, elizabeth@mcdougallpr.com, Tel: +1 (585) 435 -7379

26/04/2018

– Wiederhold’s strategic leadership will help the company as it scales and penetrates the global biotechnology market

April 25, 2018 LONDON-Synthace Ltd., the company behind the leading software platform for automating and improving the success rate of biological research, has appointed Silicon Valley veteran Bob Wiederhold as Chairman of its board of Directors. Synthace operates at the intersection of biology and information technology (IT), and Wiederhold brings deep expertise and experience to the company as a result of building multiple successful IT start ups over the last 30 years.

“I am very excited to join Synthace at this important moment in the company’s development and am eager to work closely with the team to help them realize their aspirations and market potential.”

“Information technology is at the early stages of revolutionizing biotechnology. Bob is a seasoned entrepreneur and CEO with a stellar track record for building high growth IT companies that have established leadership positions in their respective industries as well as highly successful business models. I am confident that his experience will have a tremendous impact on Synthace’s strategic direction and future growth,” said Tim Fell, CEO of Synthace. “The team is thrilled to have him on our board, and we look forward to his invaluable guidance and contributions.”

Since 2010, Bob has been the Chairman and CEO, and more recently the Executive Chairman, of Couchbase, Inc., a leader in NoSQL databases. Prior to this, Bob served as Chairman and CEO of Transitive, the worldwide leader in cross-platform virtualization with over 20M users; Transitive was acquired by IBM in December 2008. Until 2001, Bob served as CEO of Tality Corporation, the worldwide leader in electronic design services whose revenues grew to over $200M and had 1,500 employees worldwide.

Bob also held several executive general management positions at Cadence Design Systems Inc., an electronic design automation company he joined in 1985 as a small start-up and helped grow to over $1B during his 13 years at the company. Bob has served on several boards of directors including Certicom, Fanfare, and Imperas and on advisory boards at the University of Massachusetts and California Polytechnic State University at San Luis Obispo.

“Synthace has developed a remarkable product that I believe is already in the early stages of revolutionizing the biology industry. Since its inception, the company has demonstrated remarkable traction with its pharmaceutical, agritech and industrial biotechnology customer base; demonstrating its limitless capabilities”, said Wiederhold.

Wiederhold concluded, “I am very excited to join Synthace at this important moment in the company’s development and am eager to work closely with the team to help them realize their aspirations and market potential.”

About Synthace
Based in London, Synthace is developing Antha, a language and software platform specifically for biology that lets researchers aim higher and achieve better results, faster. Antha is designed to make reproducible and scalable workflows that can be readily edited and shared, and easily automated on labs’ existing equipment. In 2016, the World Economic Forum included Synthace in its selection of the world’s 30 most promising Technology Pioneers that are helping shape the Fourth Industrial Revolution – a technological revolution that will fundamentally alter the way we live, work and relate to one another. For more information, visit: www.synthace.com.

 

Contacts
Synthace
Bobby Brill
Press@synthace.com
07867488769

24/04/2018

• Funds will be used to accelerate the company’s international development and complete the registrational Phase III clinical trial of its lead product EryDex.

Milan, Italy, April 24th. 2018 – Sofinnova Partners, a leading European venture capital firm specialized in Life Sciences, announced today it has led EryDel’s €26.5 M financing. The Italian biotech company which specialized in drug delivery through red blood cells, will be using funds to boost its international development and to complete the ATTEST trial – a registrational Phase III clinical trial currently enrolling in Europe, Asia, Australia and in the United States. Next to Sofinnova Partners, existing shareholder Genextra SpA and Innogest SGR also participated to the investment.

Based in Milan (Italy), EryDel develops an innovative red-blood-cell-based drug delivery device for the treatment of rare neurodegenerative diseases. Its proprietary technology relies upon the encapsulation of drugs into red cells taken from the patient’s own blood which are then re-infused into the patient. The company is led by Luca Benatti, CEO, a serial entrepreneur who previously co-founded Newron Pharmaceuticals (NWRN). EryDel’s lead product, EryDex, has received Orphan Drug designation both from the FDA and the EMA for the treatment of Ataxia Telangiectasia (AT), a rare autosomal recessive disorder for which there is currently no established therapy. Most AT patients die in the second decade of life. Next to AT, EryDel’s technology is being developed in a wide range of additional applications.

Luca Benatti, CEO of EryDel, indicates: “We are thrilled to welcome Sofinnova Partners as our lead investor. Their unique international reach and recognized experience for building global leaders represent a huge asset at a time when EryDel is about to accelerate its growth plan”.

Graziano Seghezzi, Managing Partner at Sofinnova Partners, adds: “We have known Luca Benatti for almost two decades and followed Erydel’s development since the beginning. We believe the company is now poised for rapid growth and are happy to actively contribute to this exciting development”.

For more information, please contact:
SOFINNOVA PARTNERS
Anne Rein
Tel: +33 6 03 35 92 05
e-mail: anne.rein@strategiesimage.com

23/04/2018

• Sofinnova Partners’ appointment of Armance Bordes strengthens the firm’s support team.

Paris – April 23rd 2018. Sofinnova Partners, a leading European venture capital firm specialized in Life Sciences, has appointed Armance Bordes as General Counsel. In charge of the firm’s legal and regulatory affairs, Armance brings to Sofinnova Partners a ten-year experience in private equity.

Prior to joining Sofinnova Partners, Armance was Deputy General Counsel and Secretary of the board of directors at Eurazeo. She has supervised numerous investments and divestments in listed companies; she has been involved in particular in the IPOs of Elis and Europcar in which she has been a board member. Armance started her career as an M&A lawyer at Gibson Dunn & Crutcher, LLP in Paris. She graduated from the University of Paris I Panthéon -Sorbonne and holds a postgraduate diploma from Oxford University. She is admitted to the Paris bar.

As part of a growing support team headed by Monique Saulnier, Managing Partner & COO of Sofinnova Partners, Armance will work in close ties with Christophe Blanche, Chief Financial Officer since the end of 2016. Christophe joined the firm with a sixteen-year experience in private equity. He has worked as Chief Financial Officer in French and Luxembourg management companies, and prior to that as a senior audit manager in PricewaterhouseCoopers. Christophe is Réviseur d’Entreprises in Luxembourg and graduated from the Institut Supérieur du Commerce, a French business school.

Monique Saulnier, Managing Partner and COO of Sofinnova Partners, indicates: « We are delighted to welcome Armance in Sofinnova Partners’ support team. Her experience and acute understanding of the business is a major asset in a period of increased activity, with notably the launch of new funds such as Sofinnova Crossover I which announced a closing in April at €275 M ».

Sofinnova Partners’ support team today counts 13 people. Alongside Armance who heads legal and regulatory activity and Christophe Blanche who leads the finance and administrative activity, the support team is in charge of a diversified set of functions including Accounting Investors relations and reporting, Human Resources, IT and Deal Flow Management.

Press contact pour Sofinnova Partners
Anne Rein
anne.rein@strategiesimage.com
+33 (0) 6.03.35.92.05

19/04/2018

• Sofinnova Partners invested €10 M in the capital increase.
• Funds will be used to advance the clinical programs of the company’s portfolio compounds.
• A representative of Sofinnova Partners shall be designated at the Board of directors of Inventiva.

Paris, France, April 19th. 2018 – Sofinnova Partners, a leading European venture capital firm specialized in Life Sciences, announced today is led Inventiva Pharma (IVA) €35,5 M capital increase through its newly created Sofinnova Crossover I Fund. Sofinnova Partners invested €10 M, becoming one of the company’s largest investors.

Inventiva, listed on Euronext Paris (IVA), is a biopharmaceutical company specialized in the development of treatments for fibroticand orphan diseases, such as Non Alcoholic Steato Hepatitis (NASH), systemic scleroderma (SSc) and mucopolysaccharidosis (MPS). Inventiva has a strong technology platform built on its extensive knowledge of the mechanisms of fibrosis, a chemical library of over 240,000 molecules and cell models, including patient cells, helping accelerate the discovery of new mechanisms and therapeutic candidates for the treatment of fibrotic diseases, orphan diseases and cancers.

Funds raised will allow Inventiva to advance its portfolio of compounds in the clinic, in particular its lead compound, lanifibranor, through preparatory studies towards a Phase III trial for the treatment of NASH, a growing liver disease that affects more than 30 million people in the United States, and of systemic sclerosis an orphan disease with high unmet medical needs. Funds will also allow Inventiva to advance its second program, odiparcil, a drug candidate for the treatment of multiple forms of mucopolysaccharidosis.

Jacques Theurillat, Partner in the Sofinnova Crossover I Fund, commented: « Inventiva is exactly the type of company we are seeking to invest in with our Crossover fund: innovative technology addressing diseases of high unmet medical need with large market sizes, an experimented team backed by a prestigious international investor syndicate helping the company develop its global ambitions ».

Press contact for Sofinnova Partners
Anne Rein
Tel: +33 6 03 35 92 05
e-mail: anne.rein@strategiesimage.com

16/04/2018

PARIS – April 16, 2018 – LimFlow SA, developer of innovative, peripheral endovascular technology transforming the treatment of critical limb ischemia (CLI), today announced it has secured €27 million ($33.5 million) in an oversubscribed Series C financing. The round was led by Sofinnova Partners, with continued participation from existing round B investors Bpifrance, the French sovereign investment bank, and Balestier, a Singaporean family fund. Gérard Hascöet, Venture Partner at Sofinnova Partners, and Dr. Kinam Hong, Partner of the Sofinnova Crossover I Fund, will join the company’s board of directors. The investment is the first for the newly raised Sofinnova Crossover I Fund.
Proceeds from the Series C financing will fund the company’s major strategic initiatives through the second half of 2020, including completion of a U.S. pivotal trial for the LimFlow Percutaneous Deep Vein Arterialization System (pDVA), which will be submitted to the FDA as part of the approval process, and execution of its international commercialization strategy.
Based in Paris, LimFlow was founded in late 2012 by Dr. Martin Rothman, a world-renowned interventional cardiologist, and MD Start, a European Incubator dedicated to healthcare. The company’s proprietary and CE marked technology is a novel and purely percutaneous therapy for “no-option” CLI patients when all other revascularization efforts have been exhausted and a patient is facing a major amputation.
In the past 18 months, the company has achieved a number of key milestones, including CE Mark and acceptance into the FDA Breakthrough Devices Program. Enrollment is also currently underway in both a U.S. feasibility study of the LimFlow technology (PROMISE I) and an international post-market study (PROMISE International).
“We are gratified with the support we have received from Sofinnova Partners, a leading European venture capital firm and one of the most respected and specialized global Life Sciences investors. We are equally appreciative of the continued strong commitment from our existing investors. The new funds will enable us to continue our mission to save patients from amputation, and ultimately, save lives that might otherwise be lost,” said LimFlow CEO Dan Rose.
“LimFlow is an excellent fit for our healthcare Crossover I fund, where we seek investments in companies with game-changing technologies that address important clinical unmet needs and are led by experienced and passionate management teams,” said Dr. Hong.

About LimFlow SA
LimFlow is a private, venture-backed medical device company transforming the treatment of Critical Limb Ischemia, a growing clinical need in the face of the prevalence of diabetes, heart disease and an aging population. The LimFlow Percutaneous Deep Vein Arterialization (pDVA) System is designed to bypass blocked arteries in the leg and rush oxygenated blood back into the foot. For many patients, restoring perfusion in the lower limbs resolves chronic pain, improves quality of life, promotes wound healing and prevents major amputation. For more information, visit www.limflow.com.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together a team of professionals from all over Europe, the US and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a lead investor in start-ups and corporate spin-offs and has backed nearly 500 companies over more than 45 years, creating market leaders around the globe. Today, Sofinnova Partners has over €1.9 billion under management For more information, please visit: www.sofinnova.fr.
CAUTION: The LimFlow technology is approved for investigational use only in the United States. The LimFlow System received the CE Mark in October 2016 and is currently available commercially in Europe. The LimFlow System has not been approved for sale in the USA, Canada, or Japan.

PRESS CONTACTS:
For LimFlow SA
Michelle McAdam, Chronic Communications Inc.
Tel: (310) 902-1274
michelle@chronic-comm.com

For Sofinnova Partners
Anne REIN
Tel: +33 (0)6 03 35 92 05
anne.rein@strategiesimage.com

11/04/2018

For its third year of operation, the Toulouse-based company EnobraQ, which specializes in biotechnology, is strengthening its development and announcing changes in its structure. It notably opens up its capital to three major research structures: INRA, INSA and CNRS and confirms a second round of fundraising in 2 years for a cumulative amount of 4.9 million euros. Sofinnova Partners, Auriga Partners, Irdinov and SuperNovaInvest are reaffirming their confidence. This financial support will make it possible to pursue development on three axes, and particularly yield improvement of certain industrial productions by up to 20%.

EnobraQ recognized by his peers.
Through this new fundraising and the entry into the capital of big names in research such as INRA, INSA and CNRS, EnobraQ is demonstrating the viability of its projects over the long term. Founded by private investors at the end of 2015, EnobraQ was one of the first startups to be accompanied by Toulouse White Biotechnology (TWB) on the development of innovative projects and one of the first to receive direct support from its supervisory bodies.

2 million euros raised to materialize breakthrough innovations
With discoveries made over the past two years, EnobraQ is currently working on a project to improve the output of industrial productions by up to 20%. Thanks to its cutting-edge research on the use of CO2, it is also developing a lactic acid production process which could thus contribute to reducing the dependency on fossil products such as oil, to save resources needed for food but also help reduce carbon footprint. Finally, the company focuses on the optimization of photosynthesis through a process demonstrating a significant improvement of the enzyme allowing the fixation of CO2. In the long run, this discovery could have a positive and lasting impact on food security worldwide

Accelerating industrialization of biotechnology processes
In its new development phase, EnobraQ aims to generalize the use of CO2 as industrial feedstock.
“Today we are entering a strategic phase of our development. Our expertise of the RuBisCO in industrial biotechnology, the most widespread protein in the world, allows us to target the nutrition, bioplastics and agri-food markets. This new fundraising and the support of three major French public research centers will enable us to expand our fields of action and lead to the implementation of sustainable processes” explains Christophe Dardel, Chief Executive Officer.

About EnobraQ
EnobraQ is a start-up created in 2015, from a pre-competitive research project supported by Toulouse White Biotechnology (TWB). Concerned with ecological and economic considerations, EnobraQ develops breakthrough technologies that use CO2 and target markets as diverse as nutrition, agri-food, cosmetics, pharmacology and bioplastics.
More information at : http://enobraq.com/
Media Contact
Agence OXYGEN – Mélissa Pontéry / Aurélie Vérin
Tél : +33 5 32 11 07 36 / melissap@oxygen-rp.com

04/04/2018

World’s Only Biology-Guided Radiation Therapy Could Help Millions More Patients Worldwide

Hayward, CA – April 4, 2018 – RefleXion Medical, a medical technology company developing the first and only biology-guided radiotherapy system (BgRT) for targeted cancer treatment, announced today it has raised more than $100 million in a Series C round of funding led by The Rise Fund, the global impact investment fund managed by TPG Growth. Also participating were T. Rowe Price Associates, Inc., Chinafocused healthcare investment firm GT Healthcare Capital Partners, and all existing investors including Sofinnova Partners, KCK Group, Venrock as well as corporate investors Pfizer Venture Investments and Johnson & Johnson Innovation – JJDC Inc.

“Radiation therapy has a long history of effectively treating cancer patients. However, current systems have significant limitations our platform addresses,” said RefleXion CEO Todd Powell. “We believe many of the 600,000 U.S. patients with metastatic cancer each year could benefit from our unique ability to accurately irradiate multiple tumors in the same session. Another 750,000 U.S. patients diagnosed annually with early stage disease may benefit from our system automatically compensating for tumor motion while precisely targeting the disease.”

During BgRT procedures, cancer patients will be injected with a PET (Positron Emission Tomography) imaging tracer that accurately identifies tumors. RefleXion’s technology then directs therapeutic x-rays at one or more targets in real time, based on the tracer signals. Using this proprietary approach, RefleXion’s platform has the potential to deliver higher doses of radiation to cancerous lesions than current systems with improved sparing of surrounding healthy tissue.

“The RefleXion system is the first and only one to have a patient’s tumors guide their own treatment and destruction,” said Samuel Mazin, PhD, Founder and CTO of RefleXion. “Our goal is to eliminate disease throughout the body with solo treatments or in concert with immunotherapy and other advanced cancer drugs. We believe this could help reduce the more than 13 million global cancer deaths projected to occur in 2030 by the World Health Organization.”

Additionally, RefleXion’s technology has been shown to simplify and automate many elements of the radiotherapy treatment process. An immediate benefit could be increasing access to care in underserved areas suffering from shortages of trained technicians and qualified support staff.

“This compelling new technology has the potential to dramatically improve the health and lifespans of metastatic cancer patients around the world,” said Matthew Hobart, Partner at TPG Growth. “Investing in companies like RefleXion is core to The Rise Fund’s mission of building high-performing businesses that also create positive social impact. We’re excited to work with the team at RefleXion to help them scale the business and create a new category in cancer care.”

About RefleXion Medical
RefleXion Medical is a privately held medical device company developing the first biology-guided radiotherapy (BgRT) system for cancer treatment. By leveraging Positron Emission Tomography (PET) in a novel way, RefleXion’s patented technology will allow tumors to continuously signal their location during treatment and potentially revolutionize radiotherapy. RefleXion is backed by premier investment firms Sofinnova Partners, KCK Group, Pfizer Venture Investments, Venrock and Johnson & Johnson Innovation, JJDC Inc. The company has also received grant funding from the National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Program. For more information, visit www.reflexion.com and follow @reflexionmed on Twitter.

About TPG Growth
TPG Growth is the middle market and growth equity investment platform of TPG, the global private investment firm. With more than $13 billion of assets under management, TPG Growth targets investments in a broad range of industries and geographies. TPG Growth has the deep sector knowledge, operational resources, and global experience to drive value creation, and help companies reach their full potential. The firm is backed by the resources of TPG, which has more than $73 billion of assets under management. For more information, visit www.tpg.com.

About The Rise Fund
The Rise Fund is the world’s largest global fund committed to achieving measurable, positive social and environmental outcomes alongside outsized financial returns—referred to as “complete returns.” The Rise Fund is managed by TPG Growth, the global growth equity and middle market buyout platform of alternative asset firm TPG. TPG Growth Founder and Managing Partner Bill McGlashan, U2 lead singer Bono, a well-known activist and a special partner with TPG Growth, and Jeff Skoll, a global entrepreneur, film producer, and impact investor, co-founded The Rise Fund. They were joined by a group of influential thought leaders with a deep personal and professional commitment to driving social and environmental progress, who came together to form the Founders Board. The Rise Fund’s objectives align with the U.N.’s Sustainable Development Goals. The Rise Fund invests in education, energy, food and agriculture, financial services, growth infrastructure, healthcare, and technology, media, and telecommunications companies that deliver complete returns. For more information, visit therisefund.com.

Contacts:
RefleXion Medical
Kevin Knight
214-732-9392
kknightpr@gmail.com

The Rise Fund
Frank Thomas
212 601 4711
Fthomas@therisefund.com

04/04/2018

• Sofinnova Crossover Fund 1 is the largest healthcare crossover fund focused on Europe.
• With this new fund, Sofinnova Partners actively pursues the strategy to broaden its Life Sciences platform to invest across the value chain, from seed stage to late-stage companies.
• Bpifrance* and CNP Assurances acted as sponsors for the fund.

Paris, France – April 4th, 2018 — Sofinnova Partners, a leading European venture capital firm specialized in Life Sciences, announced today the launch of Sofinnova Crossover I with €275 million ($340 million), above the original first close target of €250 million. With this new fund, Sofinnova Partners goes one step further in the execution of its growth plan, aimed at expanding its coverage across the Life Sciences space with dedicated sector teams.

Pursuing a strategy Sofinnova Partners has successfully applied for decades with its early-stage focused Capital Funds, Sofinnova Crossover I will invest in the biopharmaceutical and medical device sectors. The fund will focus primarily on therapeutic and game-changing companies driven by experienced management. As a lead or cornerstone investor, the fund will seek to invest in about 15 late stage private and public companies. About 80% of the investments will be made in European companies, with the remaining 20% outside of Europe primarily in North America. A dedicated, highly experienced team of four partners will invest Sofinnova Crossover I, leveraging on Sofinnova Partners’ wider experience, track record and organizational support. This new fund attracted premier international investors, predominantly sovereign funds, insurance companies, corporations and family offices. Commitments came from Europe, including France, Italy, Denmark, Ireland, and Switzerland but also from Asian investors in China and Singapore. In addition to Bpifrance* and CNP Assurances, investors include a major Chinese biopharmaceutical company, the Danish State Investment fund, and family offices like Fidim or KCK representing leading industrial families in Europe and Asia.

Antoine Papiernik, Chairman of Sofinnova Partners, said, “With the launch of this new crossover activity, Sofinnova builds upon its unique early stage track record. Many of the companies we initially funded have become over the years large, billion-euro companies, and we have gained invaluable experience in helping them to the next level. This fund will complete our investment platform across the life-sciences value-chain, allowing us to fund companies from the seed stage to the late-stage.”

Jacques Theurillat, Partner in the crossover team at Sofinnova Partners, added: “The European healthcare market has matured with hundreds of late stage private and public companies looking for growth capital, and Sofinnova Partners, with its name, track record and experience, is particularly well positioned to identify the best European deals and transform them into global leaders.”

Triago acted as placement agent and Clifford Chance Europe LLP acted as legal counsel on Sofinnova Crossover I.

* Bpifrance directly and with the “Investment for the Future” Program, managed by the SGPI and operated by Bpifrance

About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together a team of professionals from all over Europe, the US and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a lead investor in start-ups and corporate spin-offs and has backed nearly 500 companies over more than 45 years, creating market leaders around the globe. Today, Sofinnova Partners has over €1.9 billion under management.